The future of anticoagulation

Paul P Dobesh, Karissa Kim, Zachary Stacy

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Anticoagulant agents, such as unfractionated heparin and warfarin, have been in use for roughly 50 years. Over the past decade, injectable agents such as low-molecular-weight heparins, pentasaccharide, and direct thrombin inhibitors have been major advances in preventing and treating thrombosis. Despite these somewhat recent additions, there is still enormous potential to improve on the pharmacokinetic and pharmacodynamic properties of these agents, as well as improve patient outcomes. There are currently a large number of anticoagulant agents (injectable and oral) that could be available for use in the next several years. Many of these new agents have unique mechanisms that may provide practitioners with anticoagulant alternatives. This review gives a detailed analysis of the anticoagulant agents that may add to our armamentarium in the management of thrombosis.

Original languageEnglish (US)
Pages (from-to)370-384
Number of pages15
JournalJournal of Pharmacy Practice
Volume17
Issue number5
DOIs
StatePublished - Oct 1 2004

Fingerprint

Anticoagulants
Thrombosis
Injections
Antithrombins
Low Molecular Weight Heparin
Warfarin
Heparin
Pharmacokinetics

Keywords

  • Anticoagulants
  • Future
  • Thrombin
  • Ximelagatran

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

The future of anticoagulation. / Dobesh, Paul P; Kim, Karissa; Stacy, Zachary.

In: Journal of Pharmacy Practice, Vol. 17, No. 5, 01.10.2004, p. 370-384.

Research output: Contribution to journalReview article

Dobesh, Paul P ; Kim, Karissa ; Stacy, Zachary. / The future of anticoagulation. In: Journal of Pharmacy Practice. 2004 ; Vol. 17, No. 5. pp. 370-384.
@article{cf856bec34f34f5dba2e2167599ebd39,
title = "The future of anticoagulation",
abstract = "Anticoagulant agents, such as unfractionated heparin and warfarin, have been in use for roughly 50 years. Over the past decade, injectable agents such as low-molecular-weight heparins, pentasaccharide, and direct thrombin inhibitors have been major advances in preventing and treating thrombosis. Despite these somewhat recent additions, there is still enormous potential to improve on the pharmacokinetic and pharmacodynamic properties of these agents, as well as improve patient outcomes. There are currently a large number of anticoagulant agents (injectable and oral) that could be available for use in the next several years. Many of these new agents have unique mechanisms that may provide practitioners with anticoagulant alternatives. This review gives a detailed analysis of the anticoagulant agents that may add to our armamentarium in the management of thrombosis.",
keywords = "Anticoagulants, Future, Thrombin, Ximelagatran",
author = "Dobesh, {Paul P} and Karissa Kim and Zachary Stacy",
year = "2004",
month = "10",
day = "1",
doi = "10.1177/0897190004271777",
language = "English (US)",
volume = "17",
pages = "370--384",
journal = "Journal of Pharmacy Practice",
issn = "0897-1900",
publisher = "SAGE Publications Inc.",
number = "5",

}

TY - JOUR

T1 - The future of anticoagulation

AU - Dobesh, Paul P

AU - Kim, Karissa

AU - Stacy, Zachary

PY - 2004/10/1

Y1 - 2004/10/1

N2 - Anticoagulant agents, such as unfractionated heparin and warfarin, have been in use for roughly 50 years. Over the past decade, injectable agents such as low-molecular-weight heparins, pentasaccharide, and direct thrombin inhibitors have been major advances in preventing and treating thrombosis. Despite these somewhat recent additions, there is still enormous potential to improve on the pharmacokinetic and pharmacodynamic properties of these agents, as well as improve patient outcomes. There are currently a large number of anticoagulant agents (injectable and oral) that could be available for use in the next several years. Many of these new agents have unique mechanisms that may provide practitioners with anticoagulant alternatives. This review gives a detailed analysis of the anticoagulant agents that may add to our armamentarium in the management of thrombosis.

AB - Anticoagulant agents, such as unfractionated heparin and warfarin, have been in use for roughly 50 years. Over the past decade, injectable agents such as low-molecular-weight heparins, pentasaccharide, and direct thrombin inhibitors have been major advances in preventing and treating thrombosis. Despite these somewhat recent additions, there is still enormous potential to improve on the pharmacokinetic and pharmacodynamic properties of these agents, as well as improve patient outcomes. There are currently a large number of anticoagulant agents (injectable and oral) that could be available for use in the next several years. Many of these new agents have unique mechanisms that may provide practitioners with anticoagulant alternatives. This review gives a detailed analysis of the anticoagulant agents that may add to our armamentarium in the management of thrombosis.

KW - Anticoagulants

KW - Future

KW - Thrombin

KW - Ximelagatran

UR - http://www.scopus.com/inward/record.url?scp=10644241799&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10644241799&partnerID=8YFLogxK

U2 - 10.1177/0897190004271777

DO - 10.1177/0897190004271777

M3 - Review article

VL - 17

SP - 370

EP - 384

JO - Journal of Pharmacy Practice

JF - Journal of Pharmacy Practice

SN - 0897-1900

IS - 5

ER -